HOLLISTON, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Chairman and Chief Executive Officer Jim Green will present and host one-on-one meetings with investors at the Sidoti Virtual Investor Conference taking place on March 22-23, 2023.
Mr. Green will present on Wednesday, March 22 at 10:00 AM ET. A live webcast of the presentation will be available here. The presentation will also be archived on the Investor Relations section of the Harvard Bioscience website for a limited period of time.
Harvard Bioscience will also host virtual one-on-one meetings with investors on Wednesday and Thursday, March 22-23, 2023.
To register for the presentation or to schedule a one-on-one meeting, please visit www.sidoti.com/events.
About Harvard Bioscience
Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in North America, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.
For more information, please visit our website at www.harvardbioscience.com.
Investor Contact:
Harvard Bioscience, Inc.
Investor Relations
(508) 893-3120
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$2.14 |
Daily Change: | -0.15 -6.55 |
Daily Volume: | 334,673 |
Market Cap: | US$93.330M |
November 07, 2024 October 03, 2024 September 18, 2024 June 06, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB